triple agonist glp 1 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Triple GLP-1 / GIP /
Description
[1] Increases in amylase and lipase In trials, tirzepatide-treated patients had a mean increase from baseline in amylase of 20% to 25% and an increase in lipase of 28% to 35%
Ready to Explore Microdosing
If this is the case, she adds that its extremely important to be in contact with the patients therapist and/or psychiatrist
Although liraglutide is the most studied GLP-1 agonist in psychiatric patients and is available in a generic form, it requires daily dosing and is less effective than the branded, once-weekly GLP-1 agonists semaglutide and tirzepatide.
Both are in the class of drugs known as GLP-1 agonists
